Posted inCardiology news
Oral PCSK9 Inhibitor Enlicitide Produces ~58% LDL‑C Reduction in Heterozygous Familial Hypercholesterolemia: A Phase 3 Randomized Trial
In adults with heterozygous familial hypercholesterolemia on statin therapy, oral enlicitide decanoate reduced LDL‑C by ~58% at 24 weeks versus placebo and was well tolerated through 52 weeks.
